CW Advisors LLC Invests $941,000 in Alphatec Holdings, Inc. $ATEC

Key Points

• CW Advisors LLC acquired 92,828 shares of Alphatec Holdings, Inc. (NASDAQ: ATEC), valued at approximately $941,000, during the first quarter of the year.
• Alphatec reported a quarterly earnings per share (EPS) of $0.02, exceeding analysts' expectations of (-$0.06), with revenue of $185.54 million.
• Currently, 66.35% of Alphatec's stock is owned by institutional investors, and several analysts have recently reiterated a "buy" rating on the company's shares.

CW Advisors LLC purchased a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 92,828 shares of the medical technology company's stock, valued at approximately $941,000. CW Advisors LLC owned 0.06% of Alphatec at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ATEC. Comerica Bank grew its stake in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after purchasing an additional 1,248 shares during the period. Quarry LP grew its stake in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares during the period. Larson Financial Group LLC acquired a new stake in shares of Alphatec during the 1st quarter worth approximately $54,000. Lazard Asset Management LLC acquired a new stake in shares of Alphatec during the 4th quarter worth approximately $76,000. Finally, State of Wyoming acquired a new stake in shares of Alphatec during the 4th quarter worth approximately $86,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Insider Buying and Selling at Alphatec

In other news, COO Scott Lish sold 36,081 shares of Alphatec stock in a transaction on Friday, August 1st. The stock was sold at an average price of $12.53, for a total transaction of $452,094.93. Following the transaction, the chief operating officer owned 708,855 shares in the company, valued at $8,881,953.15. The trade was a 4.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of Alphatec stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total value of $269,751.72. Following the transaction, the general counsel owned 438,331 shares in the company, valued at approximately $6,535,515.21. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 410,247 shares of company stock worth $5,376,804. Corporate insiders own 20.90% of the company's stock.

Alphatec Price Performance

ATEC stock traded down $0.15 during midday trading on Thursday, reaching $16.03. The stock had a trading volume of 3,588,968 shares, compared to its average volume of 3,260,872. The company's fifty day simple moving average is $12.78 and its 200 day simple moving average is $11.70. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -14.19 and a beta of 1.05. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $16.47.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The firm's revenue for the quarter was up 27.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a research note on Monday, June 16th. Piper Sandler reaffirmed an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Barclays reissued an "overweight" rating and issued a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Alphatec has a consensus rating of "Buy" and an average target price of $18.50.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.